BioSpace

Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again

Despite meeting the primary endpoints in a Phase 3 trial, shares of Zealand Pharma dropped in premarket trading Thursday as the up to 9.8% weight loss reflected inferior loss to that generated by competitors.

Por BioSpace

1 minuto de lectura
Compartir
Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again
Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again

¿Tiene noticias que compartir con el sector de eventos?

Envíe un comunicado de prensa o una noticia y llegue a miles de profesionales del sector de eventos.

Contáctenos→

Más en Health Tech

Perspectivas relacionadas